Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 12:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Double Blind Esomeprazole Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma

NCT00317044
View directory record Official record
Conditions
Asthma, GERD
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 4 Interventional

NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

NCT00206180
View directory record Official record
Conditions
Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions
esomeprazole magnesium (oral medication)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
39
States / cities
Alabaster, Alabama • Anaheim, California • Dinuba, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 4 Interventional

Esomeprazole for Treatment of GERD in Pediatric Patients

NCT00228527
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
24
States / cities
Mobile, Alabama • Phoenix, Arizona • Wilmington, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen

NCT00527787
View directory record Official record
Conditions
Gastric Ulcer
Interventions
PN400 (VIMOVO), Naproxen
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 27, 2010 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658775
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Moline, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 2 Interventional Results available

Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

NCT00474903
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Cancer
Interventions
acetylsalicylic acid, esomeprazole magnesium, placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

NCT00664560
View directory record Official record
Conditions
Osteoarthritis
Interventions
PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid
Drug
Lead sponsor
POZEN
Industry
Eligibility
50 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 2 Interventional

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

NCT00206245
View directory record Official record
Conditions
GERD With Erosive Esophagitis
Interventions
AZD0865
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
77
States / cities
Alabaster, Alabama • Huntsville, Alabama • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 18, 2026, 12:49 AM EDT
Terminated Phase 1 Interventional Results available

Viokase 16, Viokase16 Plus Nexium and Nexium Alone

NCT01142128
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Nexium (esomeprazole magnesium), Placebo to Nexium, Viokase 16 (pancrelipase) + Nexium, Viokase 16 + placebo to Nexium
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 18, 2026, 12:49 AM EDT
Terminated Phase 3 Interventional Results available

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec

NCT00594854
View directory record Official record
Conditions
Gastric Ulcer
Interventions
PN400 (VIMOVO), Diclofenac/Misoprostol
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Dexlansoprazole on Bone Homeostasis

NCT01216293
View directory record Official record
Conditions
Homeostasis, Bone and Bones
Interventions
Dexlansoprazole, Esomeprazole, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
Up to 75 Years · Female only
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
12
States / cities
San Diego, California • Walnut Creek, California • Lakewood, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 18, 2026, 12:49 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluation of Esomeprazole in Treating Gastro-esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy

NCT00222079
View directory record Official record
Conditions
Gastro-esophageal Reflux
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
Douglas Trask
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658528
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Utility of Nexium in Chronic Cough and Reflux Disease

NCT00287339
View directory record Official record
Conditions
Cough, GERD
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 4 Interventional Results available

Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US

NCT00660660
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
45
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2015 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 2 Interventional

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.

NCT00206284
View directory record Official record
Conditions
GERD Without Erosive Esophagitis
Interventions
AZD0865
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
77
States / cities
Alabaster, Alabama • Huntsville, Alabama • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 4 Interventional

Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD

NCT00295685
View directory record Official record
Conditions
GERD
Interventions
Antacids
Drug
Lead sponsor
Digestive & Liver Disease Specialists
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2009 · Synced Sep 18, 2026, 12:49 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery

NCT00361985
View directory record Official record
Conditions
Anastomotic Stricture, Morbid Obesity
Interventions
Esomeprazole
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 3 Interventional

Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients

NCT00241501
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
28
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Wilmington, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial

NCT00745849
View directory record Official record
Conditions
Vasomotor Rhinitis
Interventions
esomeprazole, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Esomeprazole in Patients With Frequent Heartburn

NCT01370525
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Sacramento, California • Seminole, Florida • Meridian, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658632
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
85
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 18, 2026, 12:49 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Esomeprazole in Patients With Frequent Heartburn

NCT01370538
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Mobile, Alabama • San Francisco, California • Westlake Village, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Sep 18, 2026, 12:49 AM EDT
Withdrawn Phase 2 Interventional

Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery

NCT03488147
View directory record Official record
Conditions
Dysphagia, GERD, Degenerative Joint Disease
Interventions
Esomeprazole, Placebo Oral Tablet
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 18, 2026, 12:49 AM EDT